Emerging Treatments for Subarachnoid Hemorrhage
CNS Neurol Disord Drug Targets. 2024 Feb 22. doi: 10.2174/0118715273279212240130065713. Online ahead of print.ABSTRACTThe current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a broad overview of the shifting paradigms in SAH care. By synthesizing the historical management protocols with contemporary therapeutic a...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2024 Category: Drugs & Pharmacology Authors: Matthew C Findlay Mrinmoy Kundu Jayson R Nelson Kyril L Cole Candace Winterton Samuel Tenhoeve Brandon Lucke-Wold Source Type: research

Emerging Treatments for Subarachnoid Hemorrhage
CNS Neurol Disord Drug Targets. 2024 Feb 22. doi: 10.2174/0118715273279212240130065713. Online ahead of print.ABSTRACTThe current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a broad overview of the shifting paradigms in SAH care. By synthesizing the historical management protocols with contemporary therapeutic a...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2024 Category: Drugs & Pharmacology Authors: Matthew C Findlay Mrinmoy Kundu Jayson R Nelson Kyril L Cole Candace Winterton Samuel Tenhoeve Brandon Lucke-Wold Source Type: research

Emerging Treatments for Subarachnoid Hemorrhage
CNS Neurol Disord Drug Targets. 2024 Feb 22. doi: 10.2174/0118715273279212240130065713. Online ahead of print.ABSTRACTThe current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a broad overview of the shifting paradigms in SAH care. By synthesizing the historical management protocols with contemporary therapeutic a...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2024 Category: Drugs & Pharmacology Authors: Matthew C Findlay Mrinmoy Kundu Jayson R Nelson Kyril L Cole Candace Winterton Samuel Tenhoeve Brandon Lucke-Wold Source Type: research

Emerging Treatments for Subarachnoid Hemorrhage
CNS Neurol Disord Drug Targets. 2024 Feb 22. doi: 10.2174/0118715273279212240130065713. Online ahead of print.ABSTRACTThe current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a broad overview of the shifting paradigms in SAH care. By synthesizing the historical management protocols with contemporary therapeutic a...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2024 Category: Drugs & Pharmacology Authors: Matthew C Findlay Mrinmoy Kundu Jayson R Nelson Kyril L Cole Candace Winterton Samuel Tenhoeve Brandon Lucke-Wold Source Type: research

Emerging Treatments for Subarachnoid Hemorrhage
CNS Neurol Disord Drug Targets. 2024 Feb 22. doi: 10.2174/0118715273279212240130065713. Online ahead of print.ABSTRACTThe current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a broad overview of the shifting paradigms in SAH care. By synthesizing the historical management protocols with contemporary therapeutic a...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2024 Category: Drugs & Pharmacology Authors: Matthew C Findlay Mrinmoy Kundu Jayson R Nelson Kyril L Cole Candace Winterton Samuel Tenhoeve Brandon Lucke-Wold Source Type: research

T Lymphocyte Interferon-gamma Response to Anaplasmataceae-related Major Surface Proteins and Ankyrin A in Fibromyalgia
CONCLUSION: Anaplasmataceae may play an aetiological role in fibromyalgia.PMID:38375844 | DOI:10.2174/0118715273274091231207101522 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - February 20, 2024 Category: Drugs & Pharmacology Authors: Basant K Puri Rosemarie Preyer Gary S Lee Armin Schwarzbach Source Type: research

T Lymphocyte Interferon-gamma Response to Anaplasmataceae-related Major Surface Proteins and Ankyrin A in Fibromyalgia
CONCLUSION: Anaplasmataceae may play an aetiological role in fibromyalgia.PMID:38375844 | DOI:10.2174/0118715273274091231207101522 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - February 20, 2024 Category: Drugs & Pharmacology Authors: Basant K Puri Rosemarie Preyer Gary S Lee Armin Schwarzbach Source Type: research

T Lymphocyte Interferon-gamma Response to Anaplasmataceae-related Major Surface Proteins and Ankyrin A in Fibromyalgia
CONCLUSION: Anaplasmataceae may play an aetiological role in fibromyalgia.PMID:38375844 | DOI:10.2174/0118715273274091231207101522 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - February 20, 2024 Category: Drugs & Pharmacology Authors: Basant K Puri Rosemarie Preyer Gary S Lee Armin Schwarzbach Source Type: research

T Lymphocyte Interferon-gamma Response to Anaplasmataceae-related Major Surface Proteins and Ankyrin A in Fibromyalgia
CONCLUSION: Anaplasmataceae may play an aetiological role in fibromyalgia.PMID:38375844 | DOI:10.2174/0118715273274091231207101522 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - February 20, 2024 Category: Drugs & Pharmacology Authors: Basant K Puri Rosemarie Preyer Gary S Lee Armin Schwarzbach Source Type: research

T Lymphocyte Interferon-gamma Response to Anaplasmataceae-related Major Surface Proteins and Ankyrin A in Fibromyalgia
CONCLUSION: Anaplasmataceae may play an aetiological role in fibromyalgia.PMID:38375844 | DOI:10.2174/0118715273274091231207101522 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - February 20, 2024 Category: Drugs & Pharmacology Authors: Basant K Puri Rosemarie Preyer Gary S Lee Armin Schwarzbach Source Type: research

T Lymphocyte Interferon-gamma Response to Anaplasmataceae-related Major Surface Proteins and Ankyrin A in Fibromyalgia
CONCLUSION: Anaplasmataceae may play an aetiological role in fibromyalgia.PMID:38375844 | DOI:10.2174/0118715273274091231207101522 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - February 20, 2024 Category: Drugs & Pharmacology Authors: Basant K Puri Rosemarie Preyer Gary S Lee Armin Schwarzbach Source Type: research

Unraveling the Emerging Niche Role of Extracellular Vesicles (EVs) in Traumatic Brain Injury (TBI)
This article explores the benefits and drawbacks of exosome treatment for traumatic brain injury while emphasizing the latest advancements in this field with clinical significance.PMID:38351688 | DOI:10.2174/0118715273288155240201065041 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - February 14, 2024 Category: Drugs & Pharmacology Authors: Sumel Ashique Radheshyam Pal Himanshu Sharma Neeraj Mishra Ashish Garg Source Type: research

Designing and Formulation of Nanocarriers for "Alzheimer's and Parkinson's" Early Detection and Therapy
CNS Neurol Disord Drug Targets. 2024 Feb 13. doi: 10.2174/0118715273297024240201055550. Online ahead of print.ABSTRACTThe potential of nanotechnology in advancing the diagnosis and treatment of neurodegenerative diseases is explored in this comprehensive literature review. Through an examination of various studies that utilize nanotechnology models. The aim of this paper is to evaluate whether these models can be considered a significant breakthrough in the field of neurodegeneration. The findings of these studies suggest that nanotechnology has the capacity to improve existing therapeutic approaches, create novel and safe...
Source: CNS and Neurological Disorders Drug Targets - February 14, 2024 Category: Drugs & Pharmacology Authors: Jakleen Abujamai Rukhsana Satar Shakeel Ahmed Ansari Source Type: research

Unraveling the Emerging Niche Role of Extracellular Vesicles (EVs) in Traumatic Brain Injury (TBI)
This article explores the benefits and drawbacks of exosome treatment for traumatic brain injury while emphasizing the latest advancements in this field with clinical significance.PMID:38351688 | DOI:10.2174/0118715273288155240201065041 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - February 14, 2024 Category: Drugs & Pharmacology Authors: Sumel Ashique Radheshyam Pal Himanshu Sharma Neeraj Mishra Ashish Garg Source Type: research

Designing and Formulation of Nanocarriers for "Alzheimer's and Parkinson's" Early Detection and Therapy
CNS Neurol Disord Drug Targets. 2024 Feb 13. doi: 10.2174/0118715273297024240201055550. Online ahead of print.ABSTRACTThe potential of nanotechnology in advancing the diagnosis and treatment of neurodegenerative diseases is explored in this comprehensive literature review. Through an examination of various studies that utilize nanotechnology models. The aim of this paper is to evaluate whether these models can be considered a significant breakthrough in the field of neurodegeneration. The findings of these studies suggest that nanotechnology has the capacity to improve existing therapeutic approaches, create novel and safe...
Source: CNS and Neurological Disorders Drug Targets - February 14, 2024 Category: Drugs & Pharmacology Authors: Jakleen Abujamai Rukhsana Satar Shakeel Ahmed Ansari Source Type: research